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Deficiency of debrancher enzyme causes Glycogen Storage Dis-
ease (GSD) type III, an autosomal recessive disorder, character-
ized by tissue accumulation of abnormally structured glycogen. 
This report reviews current clinical and molecular knowledge 
about this disorder and describes the variability at phenotype 
and genotype levels of a large group of Italian GSDIII patients.
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Introduction
Glycogen Storage Disease type III (GSDIII; Cori-
Forbes Disease; OMIM 232400) is an autosomal reces-
sive disorder due to the deficiency of amylo-1,6-glucosy-
dase, 4-α-glucantransferase enzyme (AGL, or Glycogen 
Debrancher Enzyme, GDE) which degrades glycogen 
branches releasing glucose in a two step reaction cata-
lysed by its two distinct activities. GSDIII was first ob-
served in the ’30s by van Creveld; in 1952 Illingworth 
and Cori described the abnormal structure of GSDIII gly-
cogen (1). In 1953 Forbes correlated the abnormal glyco-
gen structure with the typical symptoms of GSDIII (2). 
The AGL gene was cloned in 1992 (3).
The main clinical phenotypes of this disease are due 
to involvement of liver and/or muscle. Phenotypic ex-
pression is highly variable. GSDIII features can be dis-
tinguished in two presentations, according to patient’s 
age. Infancy and childhood are characterised by recurrent 
fasting hypoglycemia, seizures, hepatomegaly, decreased 
muscle tone and growth retardation. During childhood and 
early adulthood the symptoms seem to regress and most 
patients have only minimal signs of liver disease (4). The 
predominant symptoms in the adult form are distal weak-
ness, affecting calves and peroneal muscles mostly, and 
proximal weakness at a variable degree with a slow dis-
ease progression. Back pain and fatigue may be present. 
A number of patients show serum creatine kinase (CK) 
increase of 5-45 folds. Neuropathy may occur due to gly-
cogen storage in Schwann cells and axons. Hepatic dys-
function persists in few patients and cardiomyopathy, if 
present, is rarely severe.
Debranching enzyme is a single 1532 aminoacid 
chain weighing about 165 kDa and consisting of two 
independent catalytic activities: oligo-1,4-1,4-glucan-
transferase [EC 2.4.1.25] and amylo-1,6-glucosidase [EC 
3.2.1.33], localised in two distinct protein regions (5, 6). 
Patients with debrancher deficiency are classified into 
four types: IIIa: lack of both glucosidase and transferase 
activity in liver and muscle; IIIb: lack of both activities 
in liver only; IIIc: selective loss of glucosidase activity; 
IIId: selective loss of transferase activity. Debranching 
enzyme is encoded by 85-kb AGL gene on chromosome 
1p21. Six transcript isoforms have been isolated, alterna-
tively spliced in 5’ of the gene: the main of them, isoform 
1, is ubiquitous and is about 7.0 kb long. A large genetic 
screening led to the observation that GSDIIIb patients 
had mutations in exon 3 (7), whereas GSDIIIa arose with 
downstream mutations. At present, a formal demonstra-
tion of this is still lacking.
Clinical data
We reviewed clinical, biochemical and genetic data 
of 51 patients (26 males and 25 females) with GSD III 
from Centers throughout Italy. All had absent or severely 
reduced debranchig enzyme activity, either on red blood 
cells or muscle tissue. Median age of patients was 25.8 
years (range: 2-75).
Liver damage and structure were monitored over the 
entire lifetime of these patients: we observed an inverse 
correlation between aspartate and alanine amino trans-
ferase (AST, ALT) levels and age, with high transaminase 
levels in the first decade and in particular in the first three 
years of age and a progressive reduction in adulthood. 
Liver echography was useful to differentiate patients with 
mild or severe liver involvement. We considered four 
degrees of liver involvement as evaluated by echocardi-
ography: a) normal; b) patients with mild hepatomegaly 
and diffuse homogeneous hyperechogenicity, classified 
as having mild liver disease; c) patients with hepatome-
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galy and inhomogeneous hyperechogenicity classified in 
the moderate liver disease group; d) hepatic involution, 
cirrhosis or liver transplant were considered indicators 
of severe liver disease. Among 44 patients we found 2% 
with normal liver echography, 78% with mild, 16% with 
moderate and 4% with severe liver disease. In the first 
decade most patients (86%) showed mild liver disease, 
while only 5% of patients showed normal liver echogra-
phy; 9% of patients had moderate hepatic involvement. 
In the second decade 100% of patients had signs of mild 
liver disease. In the third decade 66.6%, 16% and 16% of 
patients presented respectively mild, moderate and severe 
hepatic involvement, while none had normal liver imag-
ing. In patients aged over 30 years, none had normal liver 
findings, 55%, 36% and 9% of this age group had respec-
tively mild, moderate and severe liver disease. Only two 
patients developed liver failure and needed liver trans-
plantation at 23 and 32 years of age respectively.
Muscular weakness and disability were evaluated us-
ing a modified Walton Functional Rating Scale (8), to take 
into consideration signs of distal lower limb weakness. 
We observed a direct correlation between age and disease 
progression, with higher functional rating scores in older 
patients. Functional impairment is very mild in patients 
younger than 35 years, who mainly have scores lower than 
2. Older patients present a higher variability of the function-
al score, ranging from 3 to 10. CK values of the entire se-
ries were instead higher among children and young adults. 
They ranged from 29 to 3097 I.U. with a mean value of 899 
in the first decade, from 57 to 6574 (mean: 2763 I.U.) in the 
second decade, from 87 to 3422 in the third decade (mean: 
1047 I.U.). Older patients showed a decrease of CK values 
probably due to progressive muscle loss.
Signs and symptoms of heart function were also 
evaluated: 45% of patients had normal echographic find-
ings, 54% had mild hypertrophy and 1% had moderate 
hypertrophy. None of the patient in our group had severe 
cardiac hypertrophy.
Molecular data
AGL gene was analyzed by direct sequence of the 
coding region and splicing sites. 35 patients could be 
completely characterized (69%), whereas only one allele 
was identified in 7 patients (14%), while 9 patients (17%) 
resulted negative. The majority of changes are represent-
ed by mutations giving rise to null alleles. The IVS21 + 
1G/A intronic change is the most frequent mutation in our 
series (23.4%). Missense mutations amount to 25% of to-
tal. Identified mutations are widespread along the whole 
gene and no particular hot spot could be found.
Grouping mutation type by severity (null vs. mis-
sense) and gathering clinical and genetic data, it came out 
that null patients have higher probability to develop more 
severe myopathic and hepatic involvements. Anyway, 
exceptions in both directions exist. Furthermore, as with 
other genetic diseases, the difficulty in establishing geno-
type-phenotype correlations is something well known 
with GSDIII. IVS21 + 1G/A is a good example in this 
sense (9). Among our patients, we observed the case of 
three genotypically identical adult patients, which were 
homozygous for the exon 21 skipping. All of them devel-
oped a severe myopathy, and hepatopathy, though at quite 
different ages and degree, but only the older of them suf-
fers from cardiopathy. A further complication comes from 
the presence of intrafamilial clinical variability.
As far as different types of GSDIII are concerned, all 
our informative patients (those older than 30: n = 19) are 
affected by GSD type IIIa.
Genetic screening on ethnically different populations 
has shown that only very few mutations are common in a 
considered geographic area, the great majority being pri-
vate mutations. The only mutation shared by Caucasians 
coming from different countries is R864X, identified in 
Mediterranean and North American population. The mu-
tation IVS6 + 3 A/G accounts for 11.7% of mutated al-
leles in Mediterranean families (10).
Therapy and perspectives
Therapy is not available for debranching enzyme def-
icit. To avoid fasting hypoglycaemia in infancy, dietary 
measures have been prospected. Frequent daytime high-
protein feedings (45% carbohydrate, 25% protein, 30% 
fat) and supplementation of uncooked corn starch before 
sleep showed to be effective in young patients with re-
gard to metabolic control and growth retardation. Effects 
of dietary measures on myopathies in adults are less well 
established even if there are reports of improvement in 
patients following high-protein diet (11).
Beside the described marked clinical and genetic 
variability, environmental effects on the GSDIII patho-
genesis are not elucidated at present. The creation of ani-
mal models for this disorder might reveal to be useful in 
defining pathogenesis and care.
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